NCT01562899 - A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 27, 2012

Primary Completion Date

April 1, 2015

Study Completion Date

April 1, 2015

Conditions

Metastatic Pancreatic AdenocarcinomaBRAF Mutated Melanoma

Interventions

DRUG

MEK162

Supplied as tablets of dosage strength 15 mg in high-density polyethylene bottles with child-resistant closure.

DRUG

AMG 479

Supplied as sterile liquid for intravenous infusion in vials in boxes. Until April 2013 a frozen formulation with a concentration of 30 mg/ml was used; from May 2013 onwards a refrigerated formulation with a concentration of 70 mg/ml was used.

Trial Locations (9)

3000

Pfizer Investigative Site, Leuven

3050

Pfizer Investigative Site, Parkville

31059

Pfizer Investigative Site, Toulouse

80131

Pfizer Investigative Site, Napoli

84103

University of Utah / Huntsman Cancer Institute Huntsman, Salt Lake City

02114

Massachusetts General Hospital Mass General 2, Boston

M5G 2M9

Pfizer Investigative Site, Toronto

08035

Pfizer Investigative Site, Barcelona

SM2 5PT

Pfizer Investigative Site, Sutton